著者
Osanai Toshiya Houkin Kiyohiro Uchiyama Shinichiro Minematsu Kazuo Taguchi Akihiko Terasaka Shunsuke
出版者
SAGE Publications
雑誌
International journal of stroke (ISSN:17474930)
巻号頁・発行日
vol.13, no.4, pp.444-448, 2018-06-01
被引用文献数
16

Rationale: MultiStem® (HLM051) is one of the promising allogenic cell products for acute ischemic stroke with strong evidence. A previous phase 2 randomized, double-blind, placebo-controlled, multicenter dose-escalation trial showed the safety of MultiStem® for acute ischemic stroke, with a time window beyond that of rt-PA and endovascular thrombectomy. We aim to obtain stronger evidence and to show the efficacy of the MultiStem® for treatment of ischemic stroke. Sample size: Estimated sample size is 220 (110 patients per group), which has 90% power at 5% significance level. Methods and design: TREASURE is a randomized, double-blind, placebo-controlled, multicenter phase 2/3 trial. The trial will be done at 31 medical centers in Japan. Patients with acute ischemic stroke including motor or speech deficit defined by a National Institution of Health Stroke Scale (NIHSS) score of 8-20 at baseline will be randomized 1:1 to receive a single intravenous infusion of MultiStem® or placebo within 18-36 h of stroke onset. Study outcomes: Primary outcome in this study is the proportion of patients with an excellent outcome at day 90 defined by the functional assessment. Trial registration: ClinicalTrials.gov (NCT02961504). Conclusion: The TREASURE trial will provide a novel treatment option and expand the therapeutic window for patients with stroke if the results are positive.

言及状況

外部データベース (DOI)

Twitter (5 users, 5 posts, 5 favorites)

Interesting paper related to $ATHX from Hokkaido University describing rationale for Japan Stroke Trial sponsored by @HealiosJapan. Kudos to wisdom_man1 on Reddit for finding this ... https://t.co/t00F5PUuT8

収集済み URL リスト